로딩 중…
StockDiggingStockDigging

Pharmicell Co.,Ltd.

005690· KOSPI
₩13,450-5.61%
2026-06-19

Price Chart

Pharmicell Co.,Ltd.+20.74%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap807.05B KRW
Revenue123.72B KRW
Net Income43.54B KRW
Total Assets168.10B KRW
Net Assets132.78B KRW
Employees146
Value
P/E18.54x
P/B6.08x
PEG0.48x
P/S6.52x
EV/EBITDA56.17x
FCF Yield4.16%
Profitability
ROE32.79%
ROA25.90%
Op. Margin31.52%
Revenue Growth35.75%
Earnings Growth38.44%
Financial Health
Debt Ratio126.60%
Total Debt19.94B KRW
FCF33.60B KRW
Cash22.88B KRW
Current Ratio6.86x
Net Debt/EBITDA-0.21x
Dividend
Div. Yield0.35%
Div. Growth150.00%
Performance
1Y Return20.74%
1M Return-11.10%
From 52W High-36.41%
1Y MDD-40.54%
Trading
Volume764,635 shares
Foreign Own.11.02%
Per Share
EPS725 KRW
BPS2,213 KRW

Company Info

CEO 김현수
Employees 146
Founded 1968
HQ 서울특별시 강남구, KR

Pharmicell, established in 1968 and renamed in 2011, is a specialized biotech company listed in 1988. It operates a biomedical division, manufacturing and selling the world's first stem cell therapy, and a biochemical division, producing pharmaceutical intermediates and eco-friendly phosphorus flame retardants, in addition to stem cell banking and cosmetics businesses. The company has developed and patented technologies for anticancer immunotherapy dendritic cells and neurological disorder treatments. Pharmicell is actively pursuing innovation through technology development in areas such as mRNA vaccine raw materials and artificial blood, and is headquartered in Gangnam-gu, Seoul.